Viatris Inc

Listed Company

VTRSCIK 0001792044NasdaqLarge AcceleratedPharmaceutical PreparationsDelawareFY ends Dec 31

Period

FY 2025

Revenue

$14.30B

Net Income

$-3.51B

Total Assets

$37.19B

Equity

$14.71B

Shares Out

1.15B

Op. Cash Flow

$2.32B

Business

Viatris Inc is a global healthcare company that develops, manufactures and supplies a broad portfolio of pharmaceutical products to patients worldwide. It offers prescription branded and generic drugs, complex and biosimilar products, OTC medicines, and support services such as diagnostic clinics, educational programs and digital health tools. The company reports four business segments—Developed Markets, Greater China, JANZ (Japan, Australia and New Zealand) and Emerging Markets—and operates an end-to-end R&D, manufacturing and commercial platform. Viatris distributes products through wholesalers, retailers, hospitals, specialty, mail-order and e‑commerce channels across more than 165 countries.

Summary from filing dated 2025-02-27

Financials

Consolidated Statement of Income

Year Ended · In millions, except per-share amounts

Concept	FY 2025 2025-12-31	FY 2024 2024-12-31	FY 2023 2023-12-31	FY 2022 2022-12-31	FY 2021 2021-12-31
Net sales	14,250	14,693	15,388	16,218	17,814
Other revenues	50	47	39	45	—
Total revenues	14,300	14,739	15,427	16,263	17,886
Cost of sales	9,286	9,116	8,988	9,766	12,311
Gross profit	5,014	5,624	6,439	6,497	5,576
Research and development	966	809	805	662	681
Acquired IPR&D	48	28	106	36	70
Selling, general and administrative	3,794	4,105	4,070	4,179	4,529
Impairment of goodwill	2,937	321	580	—	—
Litigation settlements and other contingencies, net	−69	351	112	4	329
Total operating expenses	7,677	5,614	5,672	4,882	5,610
Earnings (loss) from operations	−2,663	10	766	1,615	−34
Interest expense	471	550	573	592	636
Other expense (income), net	531	83	−10	−1,791	−6
Earnings (loss) before income taxes	−3,665	−623	203	2,813	−664
Income tax (benefit) provision	−150	11	148	735	605
Net (loss) earnings	−3,515	−634	55	2,079	−1,269
Basic (in USD per share)	−3	−0.53	0.05	1.71	−1.05
Diluted (in USD per share)	−3	−0.53	0.05	1.71	−1.05
Basic (in shares)	—	—	1,200	1,212	1,209
Diluted (in shares)	—	—	1,207	1,217	1,209

Consolidated Balance Sheet

As of · In millions, except per-share amounts

Concept	FY 2025 2025-12-31	FY 2024 2024-12-31	FY 2023 2023-12-31	FY 2022 2022-12-31	FY 2021 2021-12-31
Cash and cash equivalents	1,322	735	992	1,260	701
Accounts receivable, net	3,031	3,221	3,700	3,815	4,266
Inventories	3,999	3,854	3,470	3,520	3,978
Prepaid expenses and other current assets	1,436	1,711	2,028	1,811	1,958
Total current assets	9,789	9,521	12,976	10,635	10,903
Property, plant and equipment, net	2,614	2,666	2,760	3,025	3,189
Intangible assets, net	15,102	17,071	19,181	22,607	26,134
Goodwill	6,755	9,133	9,867	10,426	12,114
Deferred income tax benefit	1,061	753	693	926	1,333
Other assets	1,872	2,357	2,209	2,404	1,171
Total assets	37,193	41,501	47,686	50,022	54,843
Accounts payable	1,754	1,854	1,938	1,767	1,657
Income taxes payable	124	193	227	280	237
Current portion of long-term debt and other long-term obligations	1,933	8	1,943	1,259	1,878
Other current liabilities	3,283	3,725	3,394	3,441	4,620
Total current liabilities	7,094	5,779	7,777	6,746	9,884
Long-term debt	12,481	14,039	16,188	18,015	19,717
Deferred income tax liability	892	1,108	1,736	2,432	2,815
Other long-term obligations	2,015	1,939	1,517	1,757	1,934
Total liabilities	22,482	22,865	27,218	28,950	34,350
Common stock: $0.01 par value, 3,000,000,000 shares authorized; shares issued: 1,245,391,929 as of December 31, 2025 and 1,234,131,491 as of December 31, 2024	13	12	12	12	12
Additional paid-in capital	18,801	18,922	18,815	18,646	18,536
Retained (deficit) earnings	−388	3,419	4,640	5,176	3,689
Accumulated other comprehensive loss	−2,707	−3,213	−2,747	−2,761	−1,744
Stockholders Equity Parent Before Treasury Stock	15,719	19,140	20,719	21,072	—
Less: Treasury stock - at cost	1,007	504	252	0	—
Total equity	14,711	18,636	20,467	21,072	20,493
Total liabilities and equity	37,193	41,501	47,686	50,022	54,843

Consolidated Statement of Cash Flows

Year Ended · In millions, except per-share amounts

Concept	FY 2025 2025-12-31	FY 2024 2024-12-31	FY 2023 2023-12-31	FY 2022 2022-12-31	FY 2021 2021-12-31
Depreciation and amortization	2,798	2,893	2,741	3,028	4,507
Deferred income tax benefit	−477	−768	−387	−26	676
Litigation settlements and other contingencies, net	−40	275	87	−2	324
Loss on disposal of business	101	400	240	−1,754	0
Share-based compensation expense	178	146	181	116	111
Acquired IPR&D	51	12	100	46	—
Other non-cash items	969	−23	15	434	412
Accounts receivable	335	300	79	−240	59
Inventories	−106	−723	−613	−260	−428
Trade accounts payable	−168	36	315	170	−70
Income taxes	−113	219	−77	25	−700
Other operating assets and liabilities, net	−634	−151	−415	−618	−667
Net cash provided by operating activities	2,316	2,303	2,900	2,999	3,017
Cash paid for acquisitions, net of cash acquired	0	−350	−668	0	277
Capital expenditures	−379	−326	−377	−406	−457
Payments for product rights and other, net	−36	−21	−98	−37	−52
Proceeds from sale of property, plant and equipment	35	3	14	14	18
Purchases of IPR&D	−51	−12	−100	−46	—
Proceeds from sale of assets and subsidiaries	3	2,507	364	1,950	97
Purchase of marketable securities	−24	−26	−26	−30	−30
Proceeds from the sale of marketable securities	24	26	26	30	30
Net cash (used in) provided by investing activities	−428	1,801	−865	1,474	−118
Proceeds from issuance of long-term debt	0	0	300,000	1,876	1,710
Payments of long-term debt	−100,000	−3,714	−1,250	−3,663	−4,201
Payments of financing fees	−2	−5	−500,000	−2	−7
Change in short-term borrowings, net	200,000	0	300,000	−1,493	392
Purchase of ordinary shares	−501	−250	−250	0	0
Taxes paid related to net share settlement of equity awards	−30	−53	−38	−17	−17
Contingent consideration payments	−13	−32	−8	−19	−29
Cash dividends paid	−561	−575	−576	−582	−399
Non-contingent payments for product rights	0	0	−10	0	−456
Issuance of common stock	3	3	3	3	0
Other items, net	−190	295	−173	19	−5
Net cash used in financing activities	−1,294	−4,330	−2,302	−3,878	−3,012
Effect on cash of changes in exchange rates	18	−31	−3	−39	−31
Net increase (decrease) in cash, cash equivalents and restricted cash	612	−258	−269	556	−144
Interest	493	561	612	643	685

Filings

Filing historySign up free to browse every 10-K, 10-Q, 8-K, and proxy this filer has submitted to the SEC.Sign up free · Upgrade to Pro

Material Events

Material EventsTrack every 8-K filing and material event — AI-summarized, timelined, and alertable.Sign up free · Upgrade to Pro

Insiders

Insider ActivitySee executive buy/sell windows and insider trade activity over rolling 30/90/365-day windows.Sign up free · Upgrade to Pro

Institutional Holders

Institutional HoldersSee which funds hold this stock and track position changes quarter over quarter.Sign up free · Upgrade to Pro